SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (509)12/30/2010 12:02:37 PM
From: mcbio  Read Replies (2) | Respond to of 566
 
I posted notes on iHub regarding RIGL's presentation at Piper on 12/1/10 (see siliconinvestor.com ). I now see that two of the three Phase 3 pivotals are in DMARD-failure patients where FosD showed clear success in the Phase 2. And the one trial in TNF-failures may be able to be designed better given that RIGL now has an inkling why the Taski3 trial failed.